San Diego-based aFraxis is working to advance a possible drug treatment for Fragile X syndrome identified by MIT’s Susumu Tonegawa. Meanwhile Waltham, MA-based Syndax Pharmaceuticals is developing an anti-cancer drug that came out of Ron Evans’s lab at San Diego’s Salk Institute. That’s life sciences, and this is Xconomy: